Recent Updates
Recently added Catalysts
CUE Positive Sentiment Score: 75/100

Cue Biopharma to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference

Key Takeaway: Cue Biopharma, Inc. will participate in a fireside chat at the Stifel 2024 Healthcare Conference on November 19, 2024. The discussion will focus on updates related to its oncology and autoimmune disease programs, including recent Phase 1 clinical data for CUE-101 and CUE-102. The event highlights Cue Biopharma's commitment to developing its proprietary Immuno-STAT™ platform, which aims to enhance the body’s immune response safely. A live webcast of the event will be available, along with an archived version on the company's website.

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in a prominent healthcare conference demonstrates corporate visibility.
  • Presentation of data from ongoing clinical programs indicates progress in development.
  • Focus on innovative therapeutic options for cancer and autoimmune diseases aligns with market needs.

Full Press Release Details

BOSTON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, announced today that it will take part in a fireside chat at the Stifel 2024 Healthcare Conference being held in New York, NY, November 18-19, 2024.
During the fireside chat, Cue Biopharma will highlight current updates in its oncology and autoimmune disease programs. This includes discussing recent data highlights from its Phase 1 clinical programs, CUE-101 and CUE-102, presented at the recent Society for Immunotherapy of Cancer’s 39th Annual Meeting (SITC 2024).
Presentation Details
Date and Time: Tuesday, November 19 from 1:15 p.m. EST – 1:45 p.m. EST
Presenter: Daniel Passeri, M.Sc., J.D., chief executive officer, Cue Biopharma
A live and archived webcast of the fireside chat will be available on the Events page in the Investors and Media section of the Company’s website at www.cuebiopharma.com. The webcast will be archived for 30 days.
Cue Biopharma, a clinical-stage biopharmaceutical company, is developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body. The company’s proprietary platform, Immuno-STAT™ (Selective Targeting and Alteration of T cells), and biologics are designed to harness the curative potential of the body’s intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation.
Headquartered in Boston, Massachusetts, we are led by an experienced management team and independent Board of Directors with deep expertise in immunology and immuno-oncology as well as the design and clinical development of protein biologics.
Senior Director, Corporate Communications
LifeSci Communications

Frequently Asked Questions

What is Cue Biopharma focused on developing?

Cue Biopharma specializes in developing therapeutic biologics to engage and modulate disease-specific T cells for cancer and autoimmune disease.

When will Cue Biopharma participate in the Stifel 2024 Healthcare Conference?

Cue Biopharma's fireside chat at the Stifel Conference is scheduled for November 19, 2024.

Who will present at the fireside chat?

Daniel Passeri, M.Sc., J.D., CEO of Cue Biopharma, will present during the chat.

How can one access the webcast of the fireside chat?

The webcast can be accessed via the Events page on Cue Biopharma's website.

What is Immuno-STAT™?

Immuno-STAT™ is Cue Biopharma's proprietary platform for selectively modulating disease-specific T cells.

Last updated: Nov 12, 2024